Table 3.
Adjusted HbA1c values among newly treated diabetes patients*
| Black Patients (N=467) | White Patients (N=1339) | Combined Model (n=1806) | |
|---|---|---|---|
| Time (months) | 0.02 (0.02, 0.03) | 0.02 (0.02, 0.02) | 0.02 (0.02, 0.02) |
| Black race | -- | -- | 0.46 (0.28, 0.63) |
| Age at diagnosis | -0.03 (-0.05, -0.02) | -0.02 (-0.03, -0.02) | -0.02 (-0.03, -0.02) |
| Male | -0.09 (-0.41, 0.23) | -0.20 (-0.35, -0.05) | -0.16 (-0.30, -0.03) |
| Comorbidity | 0.04 (0.01, 0.07) | 0.01 (-0.004, 0.02) | 0.02 (0.003, 0.03) |
| SBP>130mmHg †‡ | -0.12 (-0.29, 0.04) | 0.13 (0.06, 0.20) | 0.08 (0.01, 0.14) |
| Total Chol.≥200mg/dL‡ | 0.01 (-0.15, 0.17) | 0.06 (-0.01, 0.13) | 0.05 (-0.01, 0.12) |
| Baseline BMI (kg/m2) †‡ | -0.003 (-0.02, 0.02) | 0.003 (-0.01, 0.01) | 0.001 (-0.01, 0.01) |
| Baseline HbA1c level‡ | 0.05 (-0.01, 0.11) | 0.06 (0.03, 0.09) | 0.06 (0.02, 0.08) |
| Baseline Medication (ref=glyburide) ‡ | |||
| Metformin | -0.45 (-0.96, 0.06) | -0.12 (-0.34, 0.10) | -0.21 (-0.41, 0.003) |
| Glipizide | 0.63 (-0.26, 1.52) | 0.15 (-0.14, 0.45) | 0.23 (-0.06, 0.53) |
| Multiple | -1.25 (-2.28, -0.23) | -0.01 (-0.56, 0.55) | -0.37 (-0.86, 0.12) |
| Other | -0.54 (-3.52, 2.43) | 0.29 (-0.24, 0.82) | 0.22 (-0.33, 0.77) |
| # of physician visits‡ | -0.22 (-0.36, -0.08) | -0.14 (-0.20,-0.08) | -0.16 (-0.22, -0.11) |
| Test strip use‡ | -0.01 (-0.01, -0.01) | -0.005 (-0.01, -0.004) | -0.01 (-0.01, -0.005) |
| Therapy intensification‡ | -0.06 (-0.26, 0.14) | 0.002 (-0.08, 0.09) | -0.02 (-0.10, 0.07) |
| Medication adherence‡ | -0.002 (-0.004, -0.001) | -0.003 (-0.004, -0.002) | -0.003 (-0.004, -0.002) |
*
Care site and neighborhood SES were included, but not significant at the 0.05 level.
†
SBP=systolic blood pressure; BMI=body mass index
‡
SBP and total cholesterol were measured annually
Baseline includes the 12 months before and including the therapy initiation month; Physician visits, HbA1c tests, test strip use, and medication adherence are measured 3 months prior to each HbA1c test; Therapy intensification indicates augmentation or increase in dose for oral diabetes medications following a lab assessed HbA1c test during the last six months.